The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Cytapheresis

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

High impact information on Cytapheresis

  • Collection of pluripotential hematopoietic stem cells by cytapheresis [1].
  • During cytapheresis for PBPC collection, citrate-containing anticoagulants should be used at the recommended ratio of 1:12, or with more anticoagulant than usual [2].
  • Although patients were very young (median age 6 years; average weight 17 kg), infusion of IL-2, cytapheresis and reinjection of LAK cells appeared feasible with the usual and transient complications observed with IL-2 [3].
  • The 24-hour shelf-life of cytapheresis platelet concentrates stored in polyvinyl chloride containers should be extended only with caution [4].
  • The mean contents of 5HT extracted from the Triton X-100-lysed platelets in random-donor platelet concentrates (PCs) were 0.39 +/- 0.19 mumol per 10(11) platelets (n = 5), the value of which was almost equal to 0.40 +/- 0.09 mumol per 10(11) platelets (n = 15) of platelets prepared by cytapheresis [5].
 

Anatomical context of Cytapheresis

 

Associations of Cytapheresis with chemical compounds

  • Peginterferon and ribavirin combination treatment was started after cytapheresis [9].
  • Cytapheresis has demonstrated effectiveness against UC and has practical use in Japan. Immunosuppressive agents including cyclosporin A and tacrolimus (FK506) have expanded the choice of medical therapies available for certain subgroups of patients [10].
  • The level of complement fragments, C3a and C5a, increased, while bradykinin concentration did not change during Adacolumn cytapheresis [6].
  • We identified possible contributing factors to ATEE occurrence: concomitant treatments with oestroprogestogen regimen, thalidomide, granulocyte-macrophage colony-stimulating factor (GM-CSF) and extracellular volume disturbances related to the cytapheresis procedure [11].
  • The other two patients relapsed rapidly and despite various kinds of treatment, such as a second course of TBI, extracorporeal irradiation of the blood, cytapheresis and combination chemotherapy consisting of pepleomycin, vincristine and a high dose of prednisolone, expired from pneumonia in 3 and 4 mo respectively [12].
 

Gene context of Cytapheresis

  • The level of TNF released showed a progressive increase from PBLs harvested from the first cytapheresis (up to 50 pg of TNF/ml) through the fourth cytapheresis (up to 2,000 pg of TNF/ml) [13].
  • The data in this study of 782 cytapheresis samples indicates that there is a negative correlation between the clonogenicity of the CD34-expressing cells and the absolute number or the proportion of CD34-expressing cells within the harvest [14].
  • A BM CD34+/CD71- cell concentration greater than or less than a cut-off value of 30/microl was significantly associated with the yield of CD34+ cells collected by cytapheresis procedures (mean values 3.12 x 10(6)/kg, and 2.19 x 10(6)/kg, respectively, P = 0.013) [15].
  • Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus [8].
  • Concerning the mechanism of cytapheresis, anti-inflammatory factors such as soluble tumor necrosis factor receptor, and interleukin-10 reduced after cytapheresis [16].
 

Analytical, diagnostic and therapeutic context of Cytapheresis

  • Since this approach seems not to have the disadvantages of pharmacological immunosuppression, further controlled studies of Adacolumn cytapheresis are warranted in SLE [8].

References

  1. Collection of pluripotential hematopoietic stem cells by cytapheresis. Lasky, L.C., Ash, R.C., Kersey, J.H., Zanjani, E.D., McCullough, J. Blood (1982) [Pubmed]
  2. Concentration of citrate anticoagulant in peripheral blood progenitor cell collections. Burger, S.R., Fautsch, S.K., Stroncek, D.F., McCullough, J. Transfusion (1996) [Pubmed]
  3. A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 cases. Favrot, M., Floret, D., Michon, J., Negrier, S., Bouffet, E., Coze, C., Gaspard, M., Cochat, P., Thiesse, P., Andreu, G. Cancer Treat. Rev. (1989) [Pubmed]
  4. The 24-hour shelf-life of cytapheresis platelet concentrates stored in polyvinyl chloride containers should be extended only with caution. Strauss, R.G., Snyder, E.L., Eckermann, I., Stewart, L. Transfusion (1987) [Pubmed]
  5. Sequestration of serotonin in stored platelets. Shimizu, T., Kato, K. Transfusion (1986) [Pubmed]
  6. In vitro and in vivo evaluation of Adacolumn cytapheresis in healthy subjects. Ramlow, W., Emmrich, J., Ahrenholz, P., Sparmann, G., Kashiwagi, N., Franz, M., Yokoyama, T., Yoshikawa, T. Journal of clinical apheresis. (2005) [Pubmed]
  7. Translation of mRNA from phytohemagglutinin-stimulated human lymphocytes: characterization of interferon mRNAs. Vaquero, C., Sancéau, J., Catinot, L., Andreu, G., Falcoff, E., Falcoff, R. J. Interferon Res. (1982) [Pubmed]
  8. Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus. Soerensen, H., Schneidewind-Mueller, J.M., Lange, D., Kashiwagi, N., Franz, M., Yokoyama, T., Ramlow, W. Rheumatol. Int. (2006) [Pubmed]
  9. Leucocytapheresis with Adacolumn enhances HCV-specific proliferative responses in patients infected with hepatitis C virus genotype 1. Diepolder, H.M., Kashiwagi, N., Teuber, G., Ulsenheimer, A., Franz, M., Yokoyama, T., Zachoval, R. J. Med. Virol. (2005) [Pubmed]
  10. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease. Hibi, T., Inoue, N., Ogata, H., Naganuma, M. J. Gastroenterol. (2003) [Pubmed]
  11. AL cardiac amyloidosis and arterial thromboembolic events. Hausfater, P., Costedoat-Chalumeau, N., Amoura, Z., Cacoub, P., Papo, T., Grateau, G., Leblond, V., Godeau, P., Piette, J.C. Scand. J. Rheumatol. (2005) [Pubmed]
  12. Total body irradiation as a primary treatment for adult T-cell leukemia. Tamura, K., Okayama, A., Koga, K., Sagawa, K., Seita, M., Tachibana, N., Tsuda, K. Jpn. J. Clin. Oncol. (1983) [Pubmed]
  13. Patterns of cytokines released by peripheral blood leukocytes of normal donors and cancer patients during interleukin-2 activation in vitro. Dupere, S., Obiri, N., Lackey, A., Emma, D., Yannelli, J., Orr, D., Birch, R., O'Connor, T.E. Journal of biological response modifiers. (1990) [Pubmed]
  14. In-vitro clonogenicity of mobilized peripheral blood CD34-expressing cells: inverse correlation to both relative and absolute numbers of CD34-expressing cells. Serke, S., Watts, M., Knudsen, L.M., Kreissig, C., Schneider, U., Schwella, N., Linch, D., Johnsen, H.E. Br. J. Haematol. (1996) [Pubmed]
  15. Bone marrow steady-state CD34+/CD71- cell content is a predictive value of rG-CSF-mobilized CD34+ cells. Osma, M.M., Ortuño, F., de Arriba, F., Lozano, M.L., Heras, I., Moraleda, J.M., Vicente, V. Bone Marrow Transplant. (1998) [Pubmed]
  16. Treatment with cytapheresis for antineutrophil cytoplasmic antibody-associated renal vasculitis and its effect on anti-inflammatory factors. Hasegawa, M., Watanabe, A., Takahashi, H., Takahashi, K., Kasugai, M., Kawamura, N., Kushimoto, H., Murakami, K., Tomita, M., Nabeshima, K., Oohashi, A., Kondou, F., Ooshima, H., Hiki, Y., Sugiyama, S. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. (2005) [Pubmed]
 
WikiGenes - Universities